Torrid Holdings (CURV) has an average rating of buy and price targets ranging from $12 to $25, according to analysts polled by Capital IQ. (MT Newswires...
Amicus Therapeutics (FOLD) forecast full-year 2022 sales from Galafold, or migalastat, for the treatment of Fabry disease will be in the range of $350...
Torrid Holdings (CURV) said Monday it now expects fiscal Q4 net sales to range from $300 million to $305 million, compared with its prior guidance of $325...
Torrid Holdings (CURV) has an average rating of buy and price targets ranging from $12 to $28, according to analysts polled by Capital IQ. (MT Newswires...
Torrid Holdings (CURV) has an average rating of buy and price targets ranging from $12 to $28, according to analysts polled by Capital IQ. (MT Newswires...
Torrid Holdings (CURV) has an average outperform rating and a price target range of $14 to $28, according to analysts polled by Capital IQ. (MT Newswires...
Torrid Holdings (CURV) has an average rating of buy and price targets ranging from $14 to $28, according to analysts polled by Capital IQ. (MT Newswires...
Consumer stocks were broadly mixed late in Thursday trading, with the SPDR Consumer Staples Select Sector ETF (XLP) climbing 0.3% while the SPDR Consumer...
Reata Pharmaceuticals (RETA) said the US Food and Drug Administration has indicated to the company that it failed to provide evidence demonstrating...
Consumer stocks were broadly mixed in Thursday trading, with the SPDR Consumer Staples Select Sector ETF (XLP) climbing 0.4% while the SPDR Consumer...